. 2020 Mar 18;2020:1973241. doi: 10.1155/2020/1973241

Table 3.

EGFR genotype and survival (PFS and TTP) of NSCLC patients treated with TKIs.

dbSNP-ID	Variant type, location, and/or consequence	Author, year (ref)	Genotyping platform used	Genotype	No. of patients (%)	Progression-free survival (PFS) (95% CI)	Time-to-progression (TTP) (95% CI)
rs11568315	Intron variant, g.55020560_55020561AC[n]	Giovannetti et al., 2010 [57]	TaqMan assay	Both alleles ≤ 16CA	30 (31.9)	NA	3.2 (0.7–5.7)^b
		Giovannetti et al., 2010 [57]	TaqMan assay	At least 1 allele > 16CA	64 (68.1)	NA	3.1 (2.4–3.8)^b
		Han et al., 2007 [55]	PCR and fragment length analysis	Both alleles ≥ 38CA	46 (53.5)	NA	Reference
		Han et al., 2007 [55]	PCR and fragment length analysis	Both alleles ≤ 37CA	40 (46.5)	NA	0.54 (0.34–0.88) ^a
		Ichihara et al., 2007 [26]	PCR and sequencing	Short allele ≥ 19CA or the sum of alleles ≥ 39CA	63 (64.3)	Reference	NA
		Ichihara et al., 2007 [26]	PCR and sequencing	Short allele < 19CA or the sum of alleles < 39CA	35 (35.7)	1.08 (0.63–1.86)^a	NA
		Kim et al., 2017 [61]	TaqMan assay and sequencing	Both alleles ≤ 16CA	74 (28.0)	Reference	NA
		Kim et al., 2017 [61]	TaqMan assay and sequencing	At least 1 allele > 16CA	188 (72.0)	0.94 (0.71–1.25)^a	NA
		Liu et al., 2008 [56]	PCR-RFLP	At least 1 allele > 16CA	59 (64.0)	Reference	NA
		Liu et al., 2008 [56]	PCR-RFLP	Both alleles ≤ 16CA	33 (36.0)	0.54 (0.33–0.88)^a	NA
		Winther Larsen et al., 2014 [59]	PCR-RFLP and capillary electrophoresis	Any allele ≤ 16CA	44 (71.0)	0.39 (0.22–0.70)^a	NA
		Winther Larsen et al., 2014 [59]	PCR-RFLP and capillary electrophoresis	Both alleles > 16CA	18 (29.0)	Reference	NA

rs2227983	Missense variant, 1562G>A, R497K	Giovannetti et al., 2010 [57]	TaqMan assay	GG or GA	81 (88.0)	NA	3.3 (2.4–5.0)^b
		Giovannetti et al., 2010 [57]	TaqMan assay	AA	11 (12.0)	NA	3.1 (1.5–4.7)^b
		Liu et al., 2008 [56]	PCR-RFLP	AA	43 (47.0)	Reference	NA
		Liu et al., 2008 [56]	PCR-RFLP	GG or GA	49 (53.0)	1.54 (0.98–2.42)^a	NA

rs2293347	Synonimous variant, 181946C>T, D994D	Winther-Larsen et al., 2015 [32]	AS-PCR or PCR followed by sequencing	CC	252 (80.0)	Reference	NA
rs2293347	Synonimous variant, 181946C>T, D994D	Winther-Larsen et al., 2015 [32]	AS-PCR or PCR followed by sequencing	CT or TT	64 (20.0)	0.74 (0.55–0.99)^a	NA

rs712829	5′ UTR variant, g.5031G>T, -216G>T	Giovannetti et al., 2010 [57]	TaqMan assay	GG	34 (36.2)	NA	3.2 (2.6–3.8)^b
		Giovannetti et al., 2010 [57]	TaqMan assay	GT or TT	60 (63.8)	NA	3.2 (0.8–5.7)^b
		Jung et al., 2012 [25]	PCR-RFLP or PCR followed by sequencing	GG	63 (88.7)	5.1 (2.7–7.5)^b	NA
		Jung et al., 2012 [25]	PCR-RFLP or PCR followed by sequencing	GT	8 (11.3)	16.6 (5.8–27.5)^b	NA
		Kim et al., 2017 [61]	Taqman PCR and sequencing	GG	78 (32.0)	Reference	NA
		Kim et al., 2017 [61]	Taqman PCR and sequencing	GT or TT	162 (68.0)	0.78 (0.59–1.03)^a	NA
		Winther-Larsen et al., 2015 [32]	AS-PCR or PCR followed by sequencing	GG	134 (42.0)	Reference	NA
		Winther-Larsen et al., 2015 [32]	AS-PCR or PCR followed by sequencing	GT or TT	182 (58.0)	0.90 (0.70–1.14)^a	NA
		Liu et al., 2008 [56]	PCR-RFLP	GG	34 (37.0)	Reference	NA
		Liu et al., 2008 [56]	PCR-RFLP	GT or TT	58 (63.0)	0.62 (0.38–0.99)^a	NA
rs712830	5′ UTR variant, g.5056A>C, -191C/A	Giovannetti et al., 2010 [57]	TaqMan assay	CC	78 (83.0)	NA	3.2 (2.5–3.9)^b
		Giovannetti et al., 2010 [57]	TaqMan assay	CA or AA	16 (17.0)	NA	3.2 (3.0–3.4)^b
		Kim et al., 2017 [61]	Taqman PCR and sequencing	CC	195 (81.0)	Reference	NA
		Kim et al., 2017 [61]	Taqman PCR and sequencing	CA or AA	45 (19.0)	1.13 (0.8–1.58)^a	NA
		Winther-Larsen et al., 2015 [32]	AS-PCR or PCR followed by sequencing	CC	236 (75.0)	Reference	NA
		Winther-Larsen et al., 2015 [32]	AS-PCR or PCR followed by sequencing	CA or AA	80 (25.0)	1.15 (0.88–1.51)^a	NA
		Liu et al., 2008 [56]	PCR-RFLP	CC	81 (88.0)	Reference	NA
		Liu et al., 2008 [56]	PCR-RFLP	CA or AA	11 (12.0)	0.86 (0.40–1.85)^a	NA

^aHazard ratio (HR); ^bMedian (months); NA–not available; in bold, significant result at the level <0.05.